share_log

Morgan Stanley Upgrades Esperion Therapeutics to Equal-Weight, Announces $9 Price Target

Morgan Stanley Upgrades Esperion Therapeutics to Equal-Weight, Announces $9 Price Target

摩根士丹利將艾斯佩里昂治療藥物升級至同等重量,宣布目標價 9 美元
Benzinga Real-time News ·  2023/02/03 06:23

Morgan Stanley analyst Jeffrey Hung upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underweight to Equal-Weight and announces $9 price target.

摩根士丹利分析師Jeffrey Hung將Esperion Treateutics(納斯達克:ESPR)的評級從減持上調至持平,並宣佈目標價為9美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論